BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th
29 sept. 2021 12h16 HE
|
BioCorRx Inc
ANAHEIM, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Files Patent Application with USPTO for Naltrexone Implant
22 sept. 2021 08h30 HE
|
BioCorRx Inc
ANAHEIM, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
08 sept. 2021 07h00 HE
|
BioCorRx Inc
SAN DIEGO, CA, and ANAHEIM, CA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO)...
BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
01 sept. 2021 08h30 HE
|
BioCorRx Inc
On track to commence the first-in-human clinical trial for BICX104 ANAHEIM, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
BioCorRx Provides Business Update for the Second Quarter of 2021
16 août 2021 08h30 HE
|
BioCorRx Inc
ANAHEIM, CA, Aug. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board
22 juin 2021 08h30 HE
|
BioCorRx Inc
ANAHEIM, CA, June 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of...
BioCorRx Provides Business Update for the First Quarter of 2021
18 mai 2021 09h05 HE
|
BioCorRx Inc
ANAHEIM, CA, May 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of...
BioCorRx Receives FDA Clearance of Investigational New Drug (IND) Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
10 mai 2021 08h30 HE
|
BioCorRx Inc
ANAHEIM, CA, May 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of...
BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone
13 avr. 2021 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, April 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of...
BioCorRx Provides 2020 Year-End Business Update
01 avr. 2021 08h30 HE
|
BioCorRx Inc
ANAHEIM, CA, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...